Status:

UNKNOWN

Cytokine Induced Killer Cells Stimulated by DC Immunotherapy for Renal Cell Carcinoma

Lead Sponsor:

Qingdao University

Conditions:

Renal Cell Carcinoma

Eligibility:

All Genders

18-75 years

Phase:

PHASE1

PHASE2

Brief Summary

30% of renal cell carcinoma patients have metastases, mostly in lung, liver and bones at the time of diagnosis. Because of poor response to radiation therapy or chemotherapy, several studies have been...

Eligibility Criteria

Inclusion

  • Female or male, adult patients of 18 to 75 years of age at time of diagnosis that qualify for standard treatment including surgery.
  • Histologically confirmed diagnosis of renal cell carcinoma.
  • Newly diagnosed or recurrent disease.
  • Karnofsky performance status 60-100.
  • Life expectancy ≥ 12 weeks.
  • Written informed consent of patient and/or legal guardian.
  • Must be off steroid at least two weeks prior to vaccination.
  • Hematologic and metabolic panel results will be within the parameters of the protocol.
  • Normal renal function in the kidney.
  • Adequate function of liver,lung and heart.
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • Serologically negative for HIV,HBV,HCV.
  • Syphilis serology negative
  • Patient must have no prior sensitivity to the components of the dendritic cell vaccine.

Exclusion

  • Anti-neoplastic chemotherapy or radiotherapy during 4 weeks before entering the study.
  • Presence of acute infection.
  • Inability to obtain informed consent because of psychiatric or complicating medical problems.
  • Patients with other significant illness including severe allergy, asthma, angina pectoris or congestive heart failure.
  • Subjects with organ allografts.
  • Known history of autoimmune disorder.
  • Pregnancy or breast-feeding.
  • Positive for hepatitis B, C, HIV, syphilis.
  • Patients unwilling to perform a save method of birth control.

Key Trial Info

Start Date :

January 1 2011

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

September 1 2013

Estimated Enrollment :

30 Patients enrolled

Trial Details

Trial ID

NCT01240005

Start Date

January 1 2011

End Date

September 1 2013

Last Update

November 15 2010

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Stem cell cencter of the affiliated hospital of medical colledge,qingdao university

Qingdao, Shandong, China, 266000

Cytokine Induced Killer Cells Stimulated by DC Immunotherapy for Renal Cell Carcinoma | DecenTrialz